Contact
Please use this form to send email to PR contact of this press release:
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor
TO:
Please use this form to send email to PR contact of this press release:
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor
TO: